

Vicky L Kett

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5387189/publications.pdf>

Version: 2024-02-01

75
papers

2,461
citations

218677

26
h-index

206112

48
g-index

76
all docs

76
docs citations

76
times ranked

2778
citing authors

#	ARTICLE	IF	CITATIONS
1	In vitro drug release, mechanical performance and stability testing of a custom silicone elastomer vaginal ring releasing dapivirine and levonorgestrel. <i>International Journal of Pharmaceutics</i> : X, 2022, 4, 100112.	1.6	0
2	Color, Scent and Size: Exploring Women's Preferences Around Design Characteristics of Drug-Releasing Vaginal Rings. <i>AIDS and Behavior</i> , 2022, , 1.	2.7	0
3	Development of a Spray-Dried Formulation of Peptide-DNA Nanoparticles into a Dry Powder for Pulmonary Delivery Using Factorial Design. <i>Pharmaceutical Research</i> , 2022, 39, 1215-1232.	3.5	14
4	Rational design and characterisation of a linear cell penetrating peptide for non-viral gene delivery. <i>Journal of Controlled Release</i> , 2021, 330, 1288-1299.	9.9	40
5	Rational design and characterisation of an amphipathic cell penetrating peptide for non-viral gene delivery. <i>International Journal of Pharmaceutics</i> , 2021, 596, 120223.	5.2	17
6	Exploiting the anticancer effects of a nitrogen bisphosphonate nanomedicine for glioblastoma multiforme. <i>Journal of Nanobiotechnology</i> , 2021, 19, 127.	9.1	5
7	The Vaginal Microbiota, Bacterial Biofilms and Polymeric Drug-Releasing Vaginal Rings. <i>Pharmaceutics</i> , 2021, 13, 751.	4.5	13
8	Silicone elastomer formulations for improved performance of a multipurpose vaginal ring releasing dapivirine and levonorgestrel. <i>International Journal of Pharmaceutics</i> : X, 2021, 3, 100091.	1.6	6
9	Use of simulated vaginal and menstrual fluids to model in vivo discolouration of silicone elastomer vaginal rings. <i>International Journal of Pharmaceutics</i> : X, 2021, 3, 100081.	1.6	5
10	Refining the in vitro release test method for a dapivirine-releasing vaginal ring to match in vivo performance. <i>Drug Delivery and Translational Research</i> , 2021, , 1.	5.8	1
11	The ins and outs of drug-releasing vaginal rings: a literature review of expulsions and removals. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 1519-1540.	5.0	16
12	DNA vaccination via RALA nanoparticles in a microneedle delivery system induces a potent immune response against the endogenous prostate cancer stem cell antigen. <i>Acta Biomaterialia</i> , 2019, 96, 480-490.	8.3	64
13	Towards a dapivirine and levonorgestrel multipurpose vaginal ring: Investigations into the reaction between levonorgestrel and addition-cure silicone elastomers. <i>International Journal of Pharmaceutics</i> , 2019, 569, 118574.	5.2	22
14	Post-use ring weight and residual drug content as potential objective measures of user adherence to a contraceptive progesterone vaginal ring. <i>Contraception</i> , 2019, 100, 241-246.	1.5	7
15	In vitro release testing methods for drug-releasing vaginal rings. <i>Journal of Controlled Release</i> , 2019, 313, 54-69.	9.9	20
16	Dapivirine-releasing vaginal rings produced by plastic freeforming additive manufacturing. <i>International Journal of Pharmaceutics</i> , 2019, 572, 118725.	5.2	47
17	Mechanical testing methods for drug-releasing vaginal rings. <i>International Journal of Pharmaceutics</i> , 2019, 559, 182-191.	5.2	22
18	Drug stability and product performance characteristics of a dapivirine-releasing vaginal ring under simulated real-world conditions. <i>International Journal of Pharmaceutics</i> , 2019, 565, 351-357.	5.2	12

#	ARTICLE	IF	CITATIONS
19	The impact of electronic prescription on reducing medication errors in an Egyptian outpatient clinic. <i>International Journal of Medical Informatics</i> , 2019, 127, 80-87.	3.3	18
20	Development and pharmacokinetics of a combination vaginal ring for sustained release of dapivirine and the protein microbicide 5P12-RANTES. <i>International Journal of Pharmaceutics</i> , 2019, 564, 207-213.	5.2	8
21	Vaginal rings with exposed cores for sustained delivery of the HIV CCR5 inhibitor 5P12-RANTES. <i>Journal of Controlled Release</i> , 2019, 298, 1-11.	9.9	34
22	DNA vaccination for cervical cancer: Strategic optimisation of RALA mediated gene delivery from a biodegradable microneedle system. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2018, 127, 288-297.	4.3	66
23	Thermal Analysis/Unconventional Techniques. , 2018, , 33-33.		0
24	Solid state ¹³ C NMR spectroscopy provides direct evidence for reaction between ethinyl estradiol and a silicone elastomer vaginal ring drug delivery system. <i>International Journal of Pharmaceutics</i> , 2018, 548, 689-697.	5.2	11
25	Intravaginal rings for continuous low-dose administration of cervical ripening agents. <i>International Journal of Pharmaceutics</i> , 2018, 549, 124-132.	5.2	10
26	Gene therapy with RALA/iNOS composite nanoparticles significantly enhances survival in a model of metastatic prostate cancer. <i>Cancer Nanotechnology</i> , 2018, 9, 5.	3.7	25
27	Impact of ring size and drug loading on the pharmacokinetics of a combination dapivirine-darunavir vaginal ring in cynomolgus macaques. <i>International Journal of Pharmaceutics</i> , 2018, 550, 300-308.	5.2	18
28	Intravaginal immunisation using a novel antigen-releasing ring device elicits robust vaccine antigen-specific systemic and mucosal humoral immune responses. <i>Journal of Controlled Release</i> , 2017, 249, 74-83.	9.9	18
29	Systemic RALA/iNOS Nanoparticles: A Potent Gene Therapy for Metastatic Breast Cancer Coupled as a Biomarker of Treatment. <i>Molecular Therapy - Nucleic Acids</i> , 2017, 6, 249-258.	5.1	20
30	Packing Polymorphism of Dapivirine and Its Impact on the Performance of a Dapivirine-Releasing Silicone Elastomer Vaginal Ring. <i>Journal of Pharmaceutical Sciences</i> , 2017, 106, 2015-2025.	3.3	19
31	Current prospects and future challenges for nasal vaccine delivery. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 34-45.	3.3	108
32	Novel freeze-dried DDA and TPGS liposomes are suitable for nasal delivery of vaccine. <i>International Journal of Pharmaceutics</i> , 2017, 533, 179-186.	5.2	22
33	Pharmacokinetics of the Protein Microbicide 5P12-RANTES in Sheep following Single-Dose Vaginal Gel Administration. <i>Antimicrobial Agents and Chemotherapy</i> , 2017, 61, .	3.2	11
34	Matrix and reservoir-type multipurpose vaginal rings for controlled release of dapivirine and levonorgestrel. <i>International Journal of Pharmaceutics</i> , 2016, 511, 619-629.	5.2	42
35	Controlling levonorgestrel binding and release in a multi-purpose prevention technology vaginal ring device. <i>Journal of Controlled Release</i> , 2016, 226, 138-147.	9.9	31
36	Development of polymeric–cationic peptide composite nanoparticles, a nanoparticle-in-nanoparticle system for controlled gene delivery. <i>International Journal of Nanomedicine</i> , 2015, 10, 7183.	6.7	14

#	ARTICLE	IF	CITATIONS
37	A Temperature-Monitoring Vaginal Ring for Measuring Adherence. PLoS ONE, 2015, 10, e0125682.	2.5	16
38	Hydrogel-Forming Microneedles Prepared from "Super Swelling" Polymers Combined with Lyophilised Wafers for Transdermal Drug Delivery. PLoS ONE, 2014, 9, e111547.	2.5	237
39	Pharmacokinetics of a CCR5 inhibitor in rhesus macaques following vaginal, rectal and oral application. Journal of Antimicrobial Chemotherapy, 2014, 69, 1325-1329.	3.0	10
40	Formulation Development of a Combination Silicone Elastomer Ring for Vaginal Delivery of Dapivirine and Levonorgestrel. AIDS Research and Human Retroviruses, 2014, 30, A138-A138.	1.1	1
41	Selection of a Hormonal Contraceptive Agent for Inclusion with Dapivirine in a Silicone Elastomer Vaginal Ring. AIDS Research and Human Retroviruses, 2014, 30, A140-A140.	1.1	2
42	Thermal Properties and Eutectic Behaviour of Dapivirine in Combination with Steroid Hormones and Other Antiretrovirals. AIDS Research and Human Retroviruses, 2014, 30, A140-A140.	1.1	3
43	Development of Reservoir Vaginal Rings Containing Dapivirine or Hormonal Contraceptive Steroids. AIDS Research and Human Retroviruses, 2014, 30, A68-A68.	1.1	2
44	Development of a Temperature-recording Vaginal Ring for Monitoring User Adherence. AIDS Research and Human Retroviruses, 2014, 30, A146-A146.	1.1	0
45	Evaluation of the Factors Contributing to Levonorgestrel Binding in Addition Cure Silicone Elastomer Vaginal Rings. AIDS Research and Human Retroviruses, 2014, 30, A139-A139.	1.1	1
46	Development of a method to quantify the DNA content in cationic peptide-DNA nanoparticles. Journal of Pharmaceutical and Biomedical Analysis, 2014, 100, 236-242.	2.8	9
47	Development and characterization of self-assembling nanoparticles using a bio-inspired amphipathic peptide for gene delivery. Journal of Controlled Release, 2014, 189, 141-149.	9.9	176
48	The effect of polymer coatings on physicochemical properties of spray-dried liposomes for nasal delivery of BSA. European Journal of Pharmaceutical Sciences, 2013, 50, 312-322.	4.0	39
49	A silicone elastomer vaginal ring for HIV prevention containing two microbicides with different mechanisms of action. European Journal of Pharmaceutical Sciences, 2013, 48, 406-415.	4.0	77
50	Investigation into the effect of varying L-leucine concentration on the product characteristics of spray-dried liposome powders. Journal of Pharmacy and Pharmacology, 2012, 64, 1412-1424.	2.4	17
51	Molecular investigations into vaginal immunization with HIV gp41 antigenic construct H4A in a quick release solid dosage form. Vaccine, 2012, 30, 2778-2785.	3.8	5
52	Intravaginal immunization using a novel antigen delivery device elicits robust vaccine antigen-specific systemic and mucosal humoral immune responses. Retrovirology, 2012, 9, .	2.0	1
53	Vaginal rings for delivery of HIV microbicides. International Journal of Women's Health, 2012, 4, 595.	2.6	77
54	Characterisation of protein stability in rod-insert vaginal rings. International Journal of Pharmaceutics, 2012, 430, 89-97.	5.2	14

#	ARTICLE	IF	CITATIONS
55	Development of liposome gel based formulations for intravaginal delivery of the recombinant HIV-1 envelope protein CN54gp140. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 46, 315-322.	4.0	47
56	Spray congealed lipid microparticles with high protein loading: Preparation and solid state characterisation. <i>European Journal of Pharmaceutical Sciences</i> , 2012, 46, 346-356.	4.0	35
57	Intravaginal immunization using the recombinant HIV-1 clade-C trimeric envelope glycoprotein CN54gp140 formulated within lyophilized solid dosage forms. <i>Vaccine</i> , 2011, 29, 4512-4520.	3.8	27
58	Volumetric properties and enthalpies of solution of alcohols $C_kH_{2k+1}OH$ ($k=1, 2, 6$) in 1-methyl-3-alkylimidazolium bis(trifluoromethylsulfonyl)imide $\{[C_1C_nIm][NTf_2] n=2, 4, 6, 8, 10\}$ ionic liquids. <i>Journal of Chemical Thermodynamics</i> , 2011, 43, 1708-1718.	2.0	31
59	Freeze-dried, mucoadhesive system for vaginal delivery of the HIV microbicide, dapivirine: Optimisation by an artificial neural network. <i>International Journal of Pharmaceutics</i> , 2010, 388, 136-143.	5.2	48
60	Selection of an analytical method for evaluating bovine serum albumin concentrations in pharmaceutical polymeric formulations. <i>Journal of Pharmaceutical and Biomedical Analysis</i> , 2010, 51, 1175-1179.	2.8	28
61	Characterisation of the Interaction of Lactate Dehydrogenase With Tween-20 Using Isothermal Titration Calorimetry, Interfacial Rheometry and Surface Tension Measurements. <i>Journal of Pharmaceutical Sciences</i> , 2009, 98, 2659-2669.	3.3	26
62	P11-11. Stable lyophilised gel vehicles for vaginal administration of recombinant C-clade HIV-1 trimeric CN54gp140. <i>Retrovirology</i> , 2009, 6, .	2.0	0
63	Calorimetric and spatial characterization of polymorphic transitions in caffeine using quasi-isothermal MTDSC and localized thermomechanical analysis. <i>Journal of Pharmaceutical Sciences</i> , 2008, 97, 1285-1300.	3.3	23
64	Investigation into the subambient behavior of aqueous mannitol solutions using temperature-controlled Raman microscopy. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2007, 67, 569-578.	4.3	19
65	Modulated Temperature Differential Scanning Calorimetry. , 2006, , 101-138.		0
66	High speed DSC (hyper-DSC) as a tool to measure the solubility of a drug within a solid or semi-solid matrix. <i>International Journal of Pharmaceutics</i> , 2005, 301, 1-5.	5.2	60
67	Thermoanalytical Techniques for the Investigation of the Freeze Drying Process and Freeze-Dried Products. <i>Current Pharmaceutical Biotechnology</i> , 2005, 6, 239-250.	1.6	14
68	Freeze-drying of protein pharmaceuticals—the application of thermal analysis. <i>Cryo-Letters</i> , 2004, 25, 389-404.	0.3	9
69	An Investigation Into the Subambient Behavior of Aqueous Mannitol Solutions Using Differential Scanning Calorimetry, Cold Stage Microscopy, and X-Ray Diffractometry. <i>Journal of Pharmaceutical Sciences</i> , 2003, 92, 1919-1929.	3.3	19
70	An Investigation into the Crystallization of α -D-Glucopyranosyl-1,6- β -D-Galactopyranoside from the Amorphous State. <i>Journal of Physical Chemistry B</i> , 2003, 107, 6614-6620.	2.6	35
71	Pharmaceutical Applications of Micro-Thermal Analysis. <i>Journal of Pharmaceutical Sciences</i> , 2002, 91, 1201-1213.	3.3	32
72	Identification of Crystalline and Amorphous Regions in Low Molecular Weight Materials Using Microthermal Analysis. <i>Journal of Physical Chemistry B</i> , 2001, 105, 7021-7026.	2.6	38

#	ARTICLE	IF	CITATIONS
73	The measurement of small quantities of amorphous material--should we be considering the rigid amorphous fraction?. <i>Pharmaceutical Research</i> , 2001, 18, 1081-1082.	3.5	23
74	An evaluation of the use of modulated temperature DSC as a means of assessing the relaxation behaviour of amorphous lactose. <i>Pharmaceutical Research</i> , 2000, 17, 696-700.	3.5	54
75	The relevance of the amorphous state to pharmaceutical dosage forms: glassy drugs and freeze dried systems. <i>International Journal of Pharmaceutics</i> , 1999, 179, 179-207.	5.2	419